CELG Celgene Corporation

   By Maria Armental 
 

Celgene Corp. (CELG) and Accord Healthcare Ltd. have resolved patent claims over blood-cancer drug Revlimid, Celgene said Thursday.

Under the terms of the settlement, Celgene said in a securities filing, Accord agreed to vacate challenges to Celgene's patents. Also, Celgene granted Accord the ability to market a generic version of Revlimid, the drug lenalidomide, for certain conditions before Celgene's patents and other restrictions in the U.K. expire beginning on Jan. 18, 2022 and in certain other European countries starting Feb. 18, 2022.

Other terms of the settlement weren't disclosed.

Celgene shares, down 23% this year, were unchanged in after-hours trading.

Write to Maria Armental at maria.armental@wsj.com

(END) Dow Jones Newswires

July 05, 2018 16:55 ET (20:55 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.